Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Medical Research Center of Miami II Inc

Neither a doctor nor a teaching hospital

Research payments

$1,031,090

181 payments

Through program year 2025, Medical Research Center of Miami II Inc is reported as receiving $1,031,090 in research payments, across 181 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $3,680 1
2024 Research $313,533 4
2023 Research $257,309 21
2022 Research $191,207 71
2021 Research $224,808 72
2020 Research $13,818 6
2019 Research $26,734 6

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sage Therapeutics, Inc. $404,338 5 payments
  2. Sanofi US Services Inc. $259,688 14 payments
  3. GlaxoSmithKline, LLC. $225,311 91 payments
  4. Biohaven Pharmaceuticals, Inc. $46,493 17 payments
  5. Boehringer Ingelheim Canada Ltd.Ltee $26,130 31 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $20,076 4 payments
  7. Paratek Pharmaceuticals, Inc. $16,649 1 payment
  8. Biohaven Pharmaceutical Holding Company Ltd. $15,081 9 payments
  9. Boehringer Ingelheim Pharma GmbH & Co.KG $11,731 6 payments
  10. AstraZeneca UK Limited $5,593 3 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Sage-718 in Participants With Mild Cognitive Impairment Or Mild Dementia Due to Alzheimer's Disease $398,371 3 payments
  2. A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis $241,741 12 payments
  3. A Descriptive, Prospective, Multi-Country, Multicentre Study to Assess $71,070 28 payments
  4. A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An $60,488 26 payments
  5. A 24-Week, Phase 3, Multicentre, Randomised, Double-Blind, Efficacy An $50,223 15 payments
  6. A Multi-Centre Long-Term Extension Study to Assess the Safety and Effi $41,213 20 payments
  7. Phase 3 Multicenter Randomized Double-blind Group Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents 6 to <18 Years of Age $34,798 11 payments
  8. BI 767551 (EX14870) Ph II/III SARS-COV-2 Ambulatory Pts IV $26,130 31 payments
  9. Phase 3 Multicenter Randomized Double-blindGroup Sequential Placebo-controlled Study to Assess Efficacy and Safety of Rimegepant or the Treatment of Migraine (With or Without Aura) in Children and Adolescents = 6 to <18 Years of Age $18,765 9 payments
  10. A Long-term Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Atopic Dermatitis Who Participated in KY1005-CT05 (DRI17366) $17,947 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record